RenalytixAI develops AI-driven clinical diagnostic solutions for kidney health, utilizing machine learning algorithms to analyze patient data and predict disease progression. The technology enables early detection of kidney disease, facilitating timely interventions that improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic kidney disease (CKD) often goes undetected in its early stages due to a lack of specific symptoms and reliance on traditional diagnostic tests that only assess current kidney function. Existing methods fail to predict which patients with type 2 diabetes and CKD are at higher risk of progressive kidney function decline, hindering timely intervention and personalized treatment strategies. This lack of early risk stratification contributes to delayed care and increased healthcare costs associated with advanced kidney disease.
Solution
Renalytix offers KidneyIntelX.dkd, a bioprognostic test that predicts the risk of progressive kidney function decline in adults with type 2 diabetes and CKD stages 1-3b. The test combines blood-based biomarkers with clinical variables, applying a machine learning algorithm to generate a risk score. This score helps clinicians identify patients at low, moderate, or high risk of rapid disease progression over the next five years. By providing early and accurate risk stratification, KidneyIntelX.dkd enables clinicians to target resources and guideline-recommended treatments more effectively, potentially slowing or preempting disease progression. The test results can be integrated with electronic health records, facilitating timely interventions and improved patient outcomes.
Target Audience
The primary target audience includes clinicians, particularly those in primary care settings, who manage adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.
Features
- Combines blood-based biomarkers and clinical data with a machine learning algorithm
- Provides a risk score indicating low, moderate, or high risk for progressive kidney function decline over five years
- Validated in large cohorts to be a highly reliable bioprognostic methodology
- FDA-approved for risk assessment of progressive kidney function decline in adults with type 2 diabetes and CKD stages 1-3b
- Included in the International KDIGO Guidelines for kidney care
- Medicare coverage determination as 'reasonable and necessary' for type 2 diabetes patients with CKD stages 1-3b
- Facilitates increased use of SGLT2i and GLP-1 RA therapies in intermediate and high-risk patients
- Integration with electronic health records for seamless data access and clinical decision support